Skip to main content

Practice Management

Practice Management
Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis
Kumar Mukherjee, PhD, Khalid M. Kamal, PhD
Kumar Mukherjee, PhD; Khalid M. Kamal, PhD
Stakeholder Perspective
Understanding Patients’ Demographics Is Key to Improving Clinical and Economic Healthcare Outcomes
F. Randy Vogenberg, RPh, PhD
by F. Randy Vogenberg, PhD, FASHP
Read More
Practice Management
Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends
Christopher B. Atzinger, MS, PhD candidate, Jeff J. Guo, BPharm, PhD
Christopher B. Atzinger, MS, PhD candidate; Jeff J. Guo, BPharm, PhD
Stakeholder Perspective
Rheumatoid Arthritis, Biologic Drugs, and Associated Cost
Byron C. Scott, MD, MBA
by Byron C. Scott, MD, MBA
Read More
Practice Management
Top 10 Healthcare Market Trends in 2017
John Santilli, MBA, F. Randy Vogenberg, PhD, FASHP
John Santilli, MBA, and F. Randy Vogenberg, RPh, PhD
Read More
Practice Management
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States
Joseph Lee, PhD, Ryan Pelkey, MS, Julieanna Gubitosa, BS, Michael F. Henrick, MBA, Michael L. Ganz, PhD
Joseph Lee, PhD; Ryan Pelkey, MS; Julieanna Gubitosa, BS; Michael F. Henrick, MBA; Michael L. Ganz, MS, PhD
Stakeholder Perspective
Identifying the Most Clinically and Economically Effective Therapies for Rheumatoid Arthritis Remains a Challenge for Providers and Payers
Gary Branning, MBA
by Gary Branning, MBA
Read More
Practice Management
BEACOPP Regimen Superior to ABVD in Newly Diagnosed, Advanced Hodgkin Lymphoma
Chase Doyle
Read More
Practice Management
Increased Utilization of Biosimilars in Oncology Could Save Payers Millions
Chase Doyle
Read More
Practice Management
Value Frameworks Unreliable in Assessing Novel Hematologic Therapies
Chase Doyle
Read More
Practice Management
Frontline Use of Bendamustine plus Rituximab Cost-Effective for Indolent B-Cell Non-Hodgkin Lymphoma
Chase Doyle
Read More
Practice Management
ASCO Value Framework Ill-Equipped to Assess Value of Therapies in Chronic Lymphocytic Leukemia
Chase Doyle
Read More
Practice Management
New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs
Chase Doyle
Read More
Page 11 of 32
Results 101 - 110 of 318